Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
JD HEALTH
06618
5
ALI HEALTH
00241
| (Q9)Sep 30, 2025 | (Q6)Jun 30, 2025 | (Q1)Mar 31, 2025 | (FY)Dec 31, 2024 | (Q9)Sep 30, 2024 | (Q6)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q9)Sep 30, 2023 | (Q6)Jun 30, 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total operating revenue | 39.02%1.32B | 36.24%896.63M | 23.26%376.2M | -21.24%1.42B | -20.31%947.83M | -18.35%658.14M | -12.64%305.21M | -22.89%1.8B | -28.18%1.19B | -27.43%806.03M |
| Operating revenue | 39.02%1.32B | 36.24%896.63M | 23.26%376.2M | -21.24%1.42B | -20.31%947.83M | -18.35%658.14M | -12.64%305.21M | -22.89%1.8B | -28.18%1.19B | -27.43%806.03M |
| Other operating revenue | ---- | 28.20%6.7M | ---- | 82.21%12.46M | ---- | 21.98%5.23M | ---- | 81.40%6.84M | ---- | 123.76%4.29M |
| Total operating cost | 21.09%1.25B | 18.86%844.49M | 8.74%382.66M | -16.97%1.56B | -18.20%1.04B | -16.57%710.49M | -8.74%351.9M | -25.17%1.88B | -26.57%1.27B | -26.76%851.56M |
| Operating cost | 34.14%834.65M | 27.77%562.63M | 18.00%240.28M | -20.86%975.99M | -23.69%622.23M | -21.80%440.35M | -15.06%203.62M | -28.34%1.23B | -32.83%815.42M | -31.73%563.12M |
| Operating tax surcharges | 89.28%11.16M | 34.10%5.39M | 53.26%1.99M | -19.11%10.94M | -24.79%5.9M | -15.68%4.02M | -42.40%1.3M | -19.29%13.53M | -23.06%7.84M | -17.94%4.77M |
| Operating expense | -1.32%153.85M | -0.01%100.99M | -6.97%49.01M | -3.18%222.63M | -4.48%155.91M | -2.05%100.99M | 6.75%52.68M | -26.68%229.93M | -4.35%163.23M | -8.74%103.11M |
| Administration expense | -7.57%97.6M | 4.95%74.18M | -3.38%39.28M | -11.18%145.31M | -4.08%105.6M | -1.58%70.68M | -1.26%40.65M | -10.94%163.6M | -14.20%110.09M | -11.76%71.82M |
| Financial expense | 34.47%-16.95M | 39.98%-13.26M | 47.93%-4.09M | -6.78%-33.05M | -1.37%-25.86M | -26.90%-22.09M | 7.88%-7.86M | -15.15%-30.95M | 14.13%-25.51M | 7.19%-17.41M |
| -Interest expense (Financial expense) | 11.53%4.69M | 16.51%3.17M | 11.03%1.57M | -36.21%5.32M | -41.39%4.21M | -27.40%2.72M | -42.87%1.42M | -42.74%8.34M | -49.02%7.18M | -48.85%3.74M |
| -Interest Income (Financial expense) | 20.62%-23.85M | 25.78%-17.95M | 30.58%-6.47M | 0.35%-38.6M | 6.35%-30.04M | -8.89%-24.19M | 21.74%-9.32M | 12.29%-38.74M | -997.18%-32.08M | -1,094.06%-22.21M |
| Research and development | 1.13%174.23M | -1.69%114.57M | -8.64%56.2M | -11.68%241.51M | -11.85%172.29M | -7.62%116.54M | -0.17%61.51M | -11.24%273.46M | -15.52%195.45M | -19.37%126.16M |
| Credit Impairment Loss | 27.24%-15.08M | -164.20%-30.31M | 91.53%-441.72K | -221.22%-138M | -366.51%-20.72M | 34.89%-11.47M | -2,599.11%-5.21M | 44.12%-42.96M | 82.16%-4.44M | 3.60%-17.62M |
| Asset Impairment Loss | -28.06%-14.69M | 44.81%-4.46M | -145.39%-7.21M | -12.43%-15.09M | -194.53%-11.47M | -141.06%-8.08M | -225.48%-2.94M | 76.31%-13.42M | 85.70%-3.89M | 77.76%-3.35M |
| Other net revenue | -47.99%20.92M | -126.37%-13.81M | -76.32%12.64M | -288.51%-78.43M | 137.89%40.23M | 3,399.30%52.39M | 406.89%53.39M | 76.53%-20.19M | 156.25%16.91M | 93.59%-1.59M |
| Fair value change income | 69.37%2M | 10.19%904.97K | 121.24%624.82K | 128.32%2M | 811.62%1.18M | 778.93%821.26K | 17.89%282.42K | 1,091.85%877.06K | -31.69%129.56K | -77.94%93.44K |
| Invest income | -69.74%11.82M | -113.62%-6.22M | -99.93%34.79K | 345.67%29.39M | 449.77%39.07M | 701.09%45.67M | 732.29%47.35M | -76.71%-11.96M | -15.36%-11.17M | -2.00%-7.6M |
| -Including: Investment income associates | 88.22%-2.01M | 20.01%-7.75M | 84.87%-1.14M | -82.92%-28.29M | -26.55%-17.1M | -7.66%-9.69M | 4.70%-7.52M | -57.85%-15.46M | -11.62%-13.51M | -2.42%-9M |
| Asset deal income | -79.39%19.32K | -117.91%-12.51K | -469.51%-17.04K | -331.39%-488.01K | -49.16%93.76K | -23.99%69.83K | -89.72%4.61K | -73.49%210.9K | 170.23%184.42K | 56.54%91.88K |
| Other revenue | 14.85%36.85M | 3.59%26.29M | 41.24%19.65M | -7.04%43.75M | -11.14%32.08M | -5.31%25.38M | -26.13%13.91M | -11.86%47.07M | 14.71%36.11M | 72.51%26.8M |
| Operating profit | 275.17%84.08M | 113,670.98%38.33M | -7.82%6.18M | -116.05%-225.06M | 20.29%-48M | 100.07%33.69K | 126.13%6.71M | 61.33%-104.17M | 39.08%-60.22M | 38.65%-47.12M |
| Add:Non operating Income | 4.05%301.81K | 210.82%209.93K | 457.82%144.52K | 26.59%982.29K | -29.12%290.05K | -92.53%67.54K | -95.92%25.91K | -93.40%775.95K | -96.14%409.21K | 262.16%904.01K |
| Less:Non operating expense | -11.17%638.55K | -71.37%204.51K | 186.75%123.3K | -13.39%1.32M | -18.00%718.88K | 31.50%714.43K | -74.08%43K | -41.27%1.52M | 56.18%876.64K | 67.12%543.31K |
| Total profit | 272.92%83.74M | 6,350.87%38.33M | -7.27%6.2M | -114.83%-225.4M | 20.20%-48.43M | 98.69%-613.21K | 126.55%6.69M | 59.68%-104.92M | 31.67%-60.68M | 39.18%-46.76M |
| Less:Income tax cost | 272.66%3.98M | -180.36%-1.2M | 843.17%2.06M | 607.22%28.77M | -125.27%-2.3M | -72.79%1.49M | 145.50%218.48K | -79.41%4.07M | 170.76%9.11M | 165.44%5.47M |
| Net profit | 272.94%79.77M | 1,980.58%39.53M | -35.99%4.14M | -133.21%-254.17M | 33.91%-46.12M | 95.98%-2.1M | 126.18%6.47M | 61.07%-108.99M | 8.08%-69.79M | 23.78%-52.23M |
| Net profit from continuing operation | 272.94%79.77M | 1,980.58%39.53M | -35.99%4.14M | -133.21%-254.17M | 33.91%-46.12M | 95.98%-2.1M | 126.18%6.47M | 61.07%-108.99M | 8.08%-69.79M | 23.78%-52.23M |
| Net income from discontinuing operating | ---- | ---- | ---- | --0 | ---- | ---- | ---- | --0 | ---- | ---- |
| Less:Minority Profit | 12,573.77%16.21M | 450.02%13.24M | 557.72%6.11M | -202.72%-17.37M | 95.60%-129.96K | 157.29%2.41M | 44.00%-1.33M | 22.66%-5.74M | -21.91%-2.96M | -36.09%-4.2M |
| Net profit of parent company owners | 238.18%63.55M | 683.10%26.29M | -125.19%-1.97M | -129.34%-236.8M | 31.19%-45.99M | 90.61%-4.51M | 134.95%7.8M | 62.12%-103.25M | 9.07%-66.84M | 26.60%-48.03M |
| Earning per share | ||||||||||
| Basic earning per share | 233.33%0.04 | 680.77%0.0151 | -124.44%-0.0011 | -133.33%-0.14 | 25.00%-0.03 | 90.58%-0.0026 | 134.88%0.0045 | 62.50%-0.06 | 5.88%-0.04 | 26.98%-0.0276 |
| Diluted earning per share | 233.33%0.04 | 680.77%0.0151 | -124.44%-0.0011 | -133.33%-0.14 | 25.00%-0.03 | 90.58%-0.0026 | 134.88%0.0045 | 62.50%-0.06 | 5.88%-0.04 | 26.98%-0.0276 |
| Other composite income | -511.87%-15.28K | -214.39%-14.52K | -109.15%-972.57 | -82.83%42.1K | -98.79%3.71K | -96.18%12.69K | 109.76%10.63K | -85.45%245.15K | -83.50%306.11K | -68.00%332.33K |
| Other composite income of parent company owners | -578.20%-14.72K | -226.63%-14.36K | -110.26%-972.57 | -105.53%-11.64K | -98.99%3.08K | -96.59%11.34K | 108.70%9.48K | -87.52%210.3K | -83.50%306.11K | -68.00%332.33K |
| Other composite income of minority owners | -188.59%-559.38 | -112.15%-164.86 | ---- | 54.19%53.73K | --631.41 | --1.36K | --1.15K | --34.85K | --0 | --0 |
| Total composite income | 272.92%79.75M | 1,991.31%39.51M | -36.11%4.14M | -133.70%-254.13M | 33.63%-46.12M | 95.97%-2.09M | 126.11%6.48M | 60.92%-108.74M | 6.20%-69.49M | 23.10%-51.89M |
| Total composite income of parent company owners | 238.16%63.54M | 684.25%26.28M | -125.18%-1.97M | -129.82%-236.81M | 30.87%-45.99M | 90.57%-4.5M | 134.83%7.81M | 61.96%-103.04M | 7.15%-66.53M | 25.93%-47.69M |
| Total composite income of minority owners | 12,634.24%16.21M | 449.70%13.24M | 558.11%6.11M | -203.63%-17.32M | 95.62%-129.33K | 157.32%2.41M | 44.05%-1.33M | 23.13%-5.7M | -21.91%-2.96M | -36.09%-4.2M |
| Currency Unit | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY |
| Accounting Standards | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) |
| Audit Opinions | -- | -- | -- | Unqualified opinion | -- | -- | -- | Unqualified opinion | -- | -- |
| Auditor | -- | -- | -- | Guangdong Sinong Accounting Firm (Special General Partnership) | -- | -- | -- | Guangdong Sinong Accounting Firm (Special General Partnership) | -- | -- |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.